|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
29,500,000 |
Market
Cap: |
40.12(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$1.365 - $4.69 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Cue Biopharma is a biopharmaceutical company engineering a class of injectable biologics to selectively engage and modulate targeted T cells directly within the patient's body. Co. is focusing on drug product candidates for treating cancer in its CUE-100 series, which exploits rationally engineered interleukin 2, in context of the key Immuno- Selective Targeting and Alteration of T Cells framework for selective activation of targeted tumor-specific T cells. Co. is seeking third party support through partnerships and collaborations, or alternative funding structures, to further develop its programs outside of oncology, including its CUE-200, CUE-300 and CUE-400 series.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
7,000 |
7,000 |
Total Buy Value |
$0 |
$0 |
$19,620 |
$19,620 |
Total People Bought |
0 |
0 |
2 |
2 |
Total Buy Transactions |
0 |
0 |
2 |
2 |
Total Shares Sold |
0 |
0 |
0 |
9,325 |
Total Sell Value |
$0 |
$0 |
$0 |
$30,586 |
Total People Sold |
0 |
0 |
0 |
1 |
Total Sell Transactions |
0 |
0 |
0 |
1 |
End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Marlett Christopher A |
Director |
|
2019-12-31 |
4 |
S |
$15.77 |
$105,659 |
I/I |
(6,700) |
768,503 |
|
-73% |
|
Marlett Christopher A |
Director |
|
2019-12-27 |
4 |
S |
$17.24 |
$155,160 |
I/I |
(9,000) |
775,203 |
|
- |
|
Marlett Christopher A |
Director |
|
2019-12-26 |
4 |
S |
$17.53 |
$344,412 |
I/I |
(19,647) |
784,203 |
|
- |
|
Marlett Christopher A |
Director |
|
2019-12-23 |
4 |
S |
$16.82 |
$285,940 |
I/I |
(17,000) |
803,850 |
|
- |
|
Marlett Christopher A |
Director |
|
2019-12-19 |
4 |
S |
$17.00 |
$68,000 |
I/I |
(4,000) |
820,850 |
|
- |
|
Marlett Christopher A |
Director |
|
2019-12-17 |
4 |
S |
$15.73 |
$326,114 |
I/I |
(20,732) |
824,850 |
|
- |
|
Marlett Christopher A |
Director |
|
2019-12-12 |
4 |
A |
$0.00 |
$0 |
I/I |
755,980 |
845,582 |
|
- |
|
Marlett Christopher A |
Director |
|
2019-12-12 |
4 |
D |
$0.00 |
$0 |
I/I |
(1,007,973) |
0 |
|
- |
|
Suri Anish |
President and CSO |
|
2019-11-01 |
4 |
D |
$8.63 |
$104,311 |
D/D |
(12,087) |
23,246 |
|
- |
|
Suri Anish |
President and CSO |
|
2019-11-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,333 |
35,333 |
|
- |
|
Fletcher Aaron G.l. |
Director |
|
2019-10-03 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
8,867 |
|
- |
|
Fletcher Aaron G.l. |
Director |
|
2019-10-03 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
150,952 |
|
- |
|
Passeri Daniel R |
CEO and President |
|
2019-06-21 |
4 |
B |
$7.26 |
$9,997 |
D/D |
1,377 |
51,977 |
2.81 |
- |
|
Sandercock Colin |
SVP, General Counsel and Sec |
|
2019-06-10 |
4/A |
B |
$7.90 |
$118,698 |
D/D |
15,025 |
17,125 |
2.74 |
- |
|
Sandercock Colin |
SVP, General Counsel and Sec |
|
2019-06-10 |
4 |
B |
$7.93 |
$118,458 |
D/D |
14,938 |
16,938 |
2.74 |
- |
|
Sandercock Colin |
SVP, General Counsel and Sec |
|
2019-06-07 |
4/A |
B |
$7.35 |
$735 |
D/D |
100 |
2,100 |
2.66 |
- |
|
Sandercock Colin |
SVP, General Counsel and Sec |
|
2019-06-06 |
4 |
B |
$7.10 |
$14,200 |
D/D |
2,000 |
2,000 |
2.74 |
- |
|
Passeri Daniel R |
CEO and President |
|
2019-06-06 |
4 |
B |
$6.90 |
$20,700 |
D/D |
3,000 |
50,600 |
2.81 |
- |
|
Marlett Christopher A |
Director |
|
2018-12-31 |
4 |
B |
$4.64 |
$85,937 |
I/I |
18,521 |
89,602 |
2.1 |
- |
|
Digiandomenico Anthony |
Director |
|
2018-12-28 |
4 |
B |
$4.62 |
$32,340 |
D/D |
7,000 |
57,000 |
2.39 |
- |
|
Digiandomenico Anthony |
Director |
|
2018-12-27 |
4 |
B |
$4.77 |
$95,400 |
D/D |
20,000 |
50,000 |
2.39 |
- |
|
Marlett Christopher A |
Director |
|
2018-12-26 |
4 |
B |
$4.29 |
$84,286 |
I/I |
19,647 |
71,081 |
2.1 |
- |
|
Digiandomenico Anthony |
Director |
|
2018-12-24 |
4 |
B |
$4.81 |
$48,100 |
D/D |
10,000 |
30,000 |
2.39 |
- |
|
Digiandomenico Anthony |
Director |
|
2018-12-21 |
4 |
B |
$4.49 |
$44,900 |
D/D |
10,000 |
20,000 |
2.39 |
- |
|
Marlett Christopher A |
Director |
|
2018-12-21 |
4 |
B |
$4.53 |
$77,916 |
I/I |
17,200 |
51,434 |
2.1 |
- |
|
113 Records found
|
|
Page 4 of 5 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|